#ipilimumab

OncLive

@onclive.bsky.social

1 month ago

Ipilimumab Plus Nivolumab With Chemoradiotherapy Leads to Bladder Preservation in Urothelial Carcinoma of the Bladder | OncLive Induction ipilimumab plus nivolumab followed by consolidative chemoradiotherapy led to bladder preservation in stage 2/3 urothelial carcinoma of the bladder.

🧪 Induction #Ipilimumab + #Nivolumab followed by chemoradiotherapy achieved 78% 2-yr bladder-intact event-free survival and strong OS signals in the INDIBLADE trial 👏 📈 @ascocancer.bsky.social #GU26 #oncology Read more➡️ www.onclive.com/view/ipilimu...

Springer Medicine

@springermedicine.com

1 month ago

Cytomegalovirus gastritis following immune checkpoint inhibitor-associated gastritis induced by ipilimumab and nivolumab therapy in a patient with renal cell carcinoma A case of immune-related gastritis complicated by subsequent cytomegalovirus gastritis in a patient undergoing combination therapy with ipilimumab and nivolumab for renal cell carcinoma.

#MedCase - A case of immune-related #gastritis complicated by subsequent CMV #gastritis in a patient undergoing combination therapy with #ipilimumab and #nivolumab for renal cell carcinoma.

👉 buff.ly/oaquChZ

#OncSky

OncoDaily

@oncodaily.bsky.social

4 months ago

Real-World Outcomes of First-Line Ipilimumab Plus Nivolumab in Advanced Renal Cell Carcinoma: Insights From the GUARDIANS Multicenter Cohort - OncoDaily Real-world data show ipilimumab + nivolumab provides meaningful survival benefits in advanced Renal Cell Carcinoma, with outcomes shaped by risk, histology, and toxicity.

Real-World Outcomes of First-Line Ipilimumab Plus Nivolumab in Advanced Renal Cell Carcinoma: Insights From the GUARDIANS Multicenter Cohort

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Ipilimumab #Nivolumab #RenalCellCarcinoma #RCC

OncoDaily

@oncodaily.bsky.social

6 months ago

Perioperative Nivolumab ± Ipilimumab in Resectable Diffuse Pleural Mesothelioma

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Nivolumab #Ipilimumab #IO #DiffusePleuralMesothelioma #Mesothelioma

Respirology Case Reports

@respcasereports.bsky.social

7 months ago

Partial Response to #Nivolumab and #Ipilimumab in a Patient With Malignant Pleural #Mesothelioma and Pre-Existing #MyastheniaGravis Without Severe Flares or Immune-Related Adverse Events: A Case Report
onlinelibrary.wiley.com/doi/10.1002/...

YesPunjab.com

@handle.invalid

8 months ago

New immunotherapy drug frees 43-year-old UK man of deadly brain tumour - Yes Punjab News UK man free from glioblastoma after immunotherapy drug trial at UCLH offers hope for brain tumour patients worldwide.

New immunotherapy drug frees 43-year-old UK man of deadly brain tumour yespunjab.com?p=142356

#Glioblastoma #CancerResearch #Immunotherapy #BrainTumourAwareness #MedicalBreakthrough #HopeForCancer #Ipilimumab #UCLH #CancerSurvivor #ClinicalTrial #BrainCancerHope #HealthNews #UKHealthcare

Respirology Case Reports

@respcasereports.bsky.social

9 months ago

A Case of PMR-Like irAE Developing After Treatment With #Ipilimumab and #Nivolumab for #LungCancer
onlinelibrary.wiley.com/doi/10.1002/...

OncoDaily

@oncodaily.bsky.social

9 months ago

Arndt Vogel: 1L Nivo Plus Low-Dose Ipi Shows Promising Results in MSI Advanced Gastric Cancer - OncoDaily Arndt Vogel: 1L Nivo Plus Low-Dose Ipi Shows Promising Results in MSI Advanced Gastric Cancer / Akitaka Makiyama, Arndt Vogel, cancer, Esophagogastric

1L Nivo Plus Low-Dose Ipi Shows Promising Results in MSI Advanced Gastric Cancer - Arndt Vogel
@arndtvogel.bsky.social

oncodaily.com/science/nivo...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Nivolumab #Ipilimumab #GastricCancer #EsophagogastricJunctionCancer #EGJ

OncoDaily

@oncodaily.bsky.social

10 months ago

No Limit trial: Results of Nivolumab+Ipilmumab in MSI-H GC Explore NO LIMIT trial's response rate with nivolumab plus low-dose ipilimumab in MSI-H advanced gastric cancer, showing durable clinical benefit.

New Paper Alert: NO LIMIT Trial. First-Line Nivolumab Plus Low-Dose Ipilimumab in MSI-High Advanced Gastric and GEJ Cancer

oncodaily.com/opinion/nivo...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NOLIMIT #Nivolumab #Ipilimumab #GEJCancer #GastricCancer

Oncology's Green Light!

@oncologygreenlight.bsky.social

10 months ago

Oncology's Green Light Podcast · OncologyResearch · FDA Approvals: AI-Powered Insights for everyday oncology clinicians

🎧 Stay informed and join the conversation! #ColorectalCancer #Immunotherapy #MSIH #dMMR #FDAapproval #Oncology #CheckMate8HW #MedicalInnovation #FDA #Nivolumab #Ipilimumab
open.spotify.com/show/6yKyfXw...

Oncology's Green Light!

@oncologygreenlight.bsky.social

10 months ago

Oncology's Green Light Podcast · OncologyResearch · FDA Approvals: AI-Powered Insights for everyday oncology clinicians

Learn about the recent FDA approval of nivolumab + ipilimumab for first-line unresectable or metastatic HCC. Stay informed and join the conversation! #HCC #Immunotherapy #FDAapproval #Oncology #Podcast #CheckMate9DW #Nivolumab #Ipilimumab open.spotify.com/show/6yKyfXw...

The Pharmaceutical Journal

@pharmaj.bsky.social

11 months ago

NICE reverses draft guidance to recommend targeted therapy for patients with advanced bowel cancer A new treatment for advanced bowel cancer has been approved by the National Institute for Health and Care Excellence (NICE) and made available on the NHS, reversing previous draft guidance that did…

#NICE has reversed previous draft guidance that did not recommend the combined immunotherapies #nivolumab (#Opdivo) and #ipilimumab (#Yervoy) for advanced bowel cancer

#cancer #bowelcancer #NHS

OncoDaily

@oncodaily.bsky.social

11 months ago

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial - OncoDaily FDA approves nivolumab and ipilimumab as first-line therapy for unresectable HCC, based on CheckMate-9DW trial results.

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial
@fda.gov

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FDA #Nivolumab #Ipilimumab #HepatocellularCarcinoma

VJOncology

@vjoncology.bsky.social

1 year ago

Intracranial CD1c/CD141 myeloid dendritic cells with ipilimumab & nivolumab in high-grade glioma - VJOncology Bart Neyns, MD, PhD, Universitair Ziekenhuis Brussel, Brussels, Belgium, discusses findings from a Phase I trial (NCT03233152) of intracranial administration...

March is #BrainTumorAwarenessMonth in the UK🧠

In a Phase I trial (NCT03233152), researchers investigated #intracranial administration of #nivolumab, #ipilimumab & #autologous #myeloid dendritic cells (myDC) in patients with recurrent high-grade #glioma following tumor resection

👉

Thiard News@F4F

@newsen.bsky.social

1 year ago

Innovent's Novel CTLA-4 Inhibitor Gains Priority Review for Colon Cancer Treatment in China Innovent Biologics receives a Priority Review from China's NMPA for ipilimumab injection as a neoadjuvant therapy in colon cancer treatment, marking a significant milestone.

Innovent's Novel CTLA-4 Inhibitor Gains Priority Review for Colon Cancer Treatment in China #China #Suzhou #Innovent_Biologics #Ipilimumab #Sintilimab

The Lancet Oncology

@thelancetoncol.bsky.social

1 year ago

Online First: 7-year follow-up of the ABC study:

#Ipilimumab plus #nivolumab versus nivolumab alone in patients with #melanoma #brainmetastases: a multicentre, open-label, randomised, phase 2 study

https://buff.ly/3X44fOt

Ray DuBois MD PhD

@duboisrn.bsky.social

1 year ago

Combination of #nivolumab and #ipilimumab in patients with metastatic #colorectalcancer (MSI-high) led to 24-month progression-free survival of 72%, as compared with 14% with #chemotherapy: www.nejm.org/doi/full/10....

OncoDaily

@oncodaily.bsky.social

1 year ago

Dr. Jason Luke's Journey in Immuno-Oncology Innovation - OncoDaily Dr. Jason Luke's Journey in Immuno-Oncology Innovation / anti-CTLA-4, cancer, immunotherapy, ipilimumab, Jason J Luke, Melanoma, OncoDaily, Oncology, Ravi Kara

Dr. Jason Luke’s Journey in Immuno-Oncology Innovation

oncodaily.com/dialogues/jo...

#AntiCTLA4 #Cancer #Immunotherapy #Ipilimumab #Melanoma #OncoDaily #Oncology #Medicine #Health

Pierre Gholam MD

@livermd.bsky.social

1 year ago

A lot to unpack but checkmate 9DW #nivolumab #ipilimumab in unresectable #HCC just dropped @ASCO
✅OS data impressive HR 0.79 but clearly subsequent therapies are confounding
✅ 3 year survival 38%!
✅ tricky to interpret because LEN/SOR comparator which I like
#livertwitter